Darunavir

Fidelia Bernice, Pharm.D., BCIDP
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS
Darunavir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • HIV-infected patients who are treatment-experienced and have at least one DRV resistance mutation, in combination with other antiretrovirals (DRV/r 600/100 mg twice daily).
  • HIV-infected patients who are treatment-naive (DRV/r 800/100 mg once daily or DRV/c 800/150 mg once daily).
  • HIV-infected children (>3 years)

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • HIV-infected patients who are treatment-experienced and have at least one DRV resistance mutation, in combination with other antiretrovirals (DRV/r 600/100 mg twice daily).
  • HIV-infected patients who are treatment-naive (DRV/r 800/100 mg once daily or DRV/c 800/150 mg once daily).
  • HIV-infected children (>3 years)

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: November 7, 2020